Activity

Filter

Cancel
Date Panel Item Activity
10 actions
Hydrops fetalis v0.189 FLVCR2 Zornitza Stark Marked gene: FLVCR2 as ready
Hydrops fetalis v0.189 FLVCR2 Zornitza Stark Gene: flvcr2 has been classified as Red List (Low Evidence).
Hydrops fetalis v0.189 FLVCR2 Zornitza Stark Phenotypes for gene: FLVCR2 were changed from Cystic hygroma; hydrops; hydranencephal; arthrogryposis to Cystic hygroma; hydrops; hydranencephaly; arthrogryposis; Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, MIM# 225790
Hydrops fetalis v0.188 FLVCR2 Zornitza Stark Publications for gene: FLVCR2 were set to PMID: 30712878
Hydrops fetalis v0.187 FLVCR2 Zornitza Stark Classified gene: FLVCR2 as Red List (low evidence)
Hydrops fetalis v0.187 FLVCR2 Zornitza Stark Gene: flvcr2 has been classified as Red List (Low Evidence).
Hydrops fetalis v0.186 FLVCR2 Zornitza Stark changed review comment from: Single case reported as part of big prenatal series.; to: Single case reported with cystic hygroma as part of big prenatal series. More typical presentation is with hydrocephalus, fetal akinesia, polyhydramnios.
Hydrops fetalis v0.186 FLVCR2 Zornitza Stark edited their review of gene: FLVCR2: Changed phenotypes: Cystic hygroma, Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, MIM# 225790
Hydrops fetalis v0.186 FLVCR2 Zornitza Stark reviewed gene: FLVCR2: Rating: RED; Mode of pathogenicity: None; Publications: 30712878; Phenotypes: Cystic hygroma; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal
Hydrops fetalis v0.186 FLVCR2 John Christodoulou gene: FLVCR2 was added
gene: FLVCR2 was added to Hydrops fetalis. Sources: Other
Mode of inheritance for gene: FLVCR2 was set to BIALLELIC, autosomal or pseudoautosomal
Publications for gene: FLVCR2 were set to PMID: 30712878
Phenotypes for gene: FLVCR2 were set to Cystic hygroma; hydrops; hydranencephal; arthrogryposis
Penetrance for gene: FLVCR2 were set to unknown
Review for gene: FLVCR2 was set to RED
Added comment: In this prospective cohort study, the parents of fetuses who were found to have a structural anomaly in a prenatal ultrasound were screened for possible participation in the study.

DNA samples from 234 (45%) eligible trios were therefore used for analysis of the primary outcome. By use of trio sequence data, we identified diagnostic genetic variants in 24 (10%) families. Mutations with bioinformatic signatures that were indicative of pathogenicity but with insufficient evidence to be considered diagnostic were also evaluated; 46 (20%) of the 234 fetuses assessed were found to have such signatures.
Sources: Other